Background {#Sec1}
==========

The diagnosis of latent tuberculosis (TB) relies on the demonstration of an acquired cell-mediated immune response to *Mycobacterium tuberculosis* (Mtb) in an otherwise asymptomatic person, either by Tuberculin skin testing (TST) or Interferon gamma release assays (IGRA) (e.g., QuantiFERON®-TB Gold in-tube (QFT-GIT) and T-SPOT.*TB*) \[[@CR1]\].

HIV-1 infection results in the depletion of Mtb specific CD4 cells \[[@CR2]\] and impaired effector responses to Mtb antigens, which could result in a false negative test for latent TB. For TST, where diameter of skin induration is measured, a lower cut-off of 5 mm rather than 10 mm is therefore commonly used to improve sensitivity \[[@CR3]\]. Alternatively a 2-stage testing approach, where the TST is repeated 1--4 weeks after an initial negative test, improves sensitivity. The initial TST is thought to boost a weak pre-existing antigen specific response, resulting in a positive test when repeated \[[@CR4]\].

Unlike TST, IGRAs have adopted a single cut-off (QFT-GIT TBAg-Nil \> 0.35 IU/mL, T-SPOT.*TB* \> 5 spots) regardless of HIV-1 status. HIV-1 co-infection however has been shown to result in a reduced sensitivity of both IGRA platforms for tuberculosis \[[@CR5], [@CR6]\]. Boosting of interferon gamma release from circulating blood cells following TST has been observed within 3 days of administration \[[@CR7]\]. This can result in conversion of IGRA from negative to positive, but occurs in less than 5 % of TST negative/IGRA negative cases in HIV-uninfected populations \[[@CR8]--[@CR11]\]. The impact of TST on IGRA conversion in immunocompromised persons such as those with HIV-1 infection has not been assessed.

In this study we evaluated the impact of TST on QFT-GIT conversion in HIV-1-infected persons that were initially TST and QFT-GIT negative and hence considered as not having evidence of latent infection. We then aimed to evaluate differences in baseline QFT-GIT response between those that converted and those that did not.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The study was conducted, in Khayelitsha, Cape Town, within the screening period of a TB vaccine trial, which enrolled participants between August 2011 and April 2013 \[[@CR12]\]. The study adhered to International Conference on Harmonisation Good Clinical Practice guidelines, and was approved by the University of Cape Town's Faculty of Health Sciences Human Research Ethics Committee. All participants provided written informed consent. Healthy HIV-1-infected adults with baseline CD4 counts above 350/mm^3^, if not receiving antiretroviral therapy (ART), or above 300/mm^3^ with suppressed HIV viral load, if receiving ART, were eligible for the vaccine trial. As part of the screening process all participants were assessed for active TB by symptom screen, chest radiograph (CXR) and sputum culture and for latent TB by QFT-GIT followed by TST. Those with no evidence of active or latent TB were eligible for randomization into the vaccine trial. However, if \> 45 days had elapsed since screening initiation, the protocol determined that participants should be rescreened prior to randomization. This included repeating the QFT-GIT. In March 2012 there was a brief sponsor initiated suspension in recruitment to the vaccine trial. As a result when recruitment was reinitiated in April 2012 a number of screened participants breeched the 45-day rule and required rescreening. This pause in recruitment allowed assessment of boosting of the response following the initial TST presented here. The study was observational and did not have a control arm.

Tuberculin skin testing and QFT-GIT {#Sec4}
-----------------------------------

TST was administered as an intradermal injection of 2TU (0.1ML) of PPD-RT23 (Statens Serum Institut, Copenhagen, Denmark) into the volar aspect of the forearm and performed immediately after blood had been drawn for baseline QFT-GIT. Maximal transverse induration was measured at 48--72 h by clinical research nurses trained to do so. Induration \< 5 mm was considered negative.

The QFT-GIT assay (Qiagen, Valencia, CA) was performed in accordance with manufacturer's instructions. The following measures were implemented in order to minimise variation in assay results: (1) All samples were taken by research nurses trained and assessed to ensure consistent sampling methodology. (2) Following blood draw samples were kept in temperature-logged insulated transport boxes and samples were incubated within 4 h of blood draw. (3) Incubation time was standardized to 24 h. (4) QFT-GIT assay was performed by Good Laboratory Practice (GLP) trained research technicians in a Foundation of Innovative New Diagnostics (FIND) accredited laboratory with regular sponsor mandated Quality Assurance (QA) undertaken to ensure reproducibility of results.

Statistical methods {#Sec5}
-------------------

Statistical analysis was conducted in Stata ver. 12.1 (StataCorp). Gaussian distribution of data was determined by the Shapiro-Wilk test. Non-parametric independent data was compared using Mann-Whitney *U* test and parametric data compared using *t*-test. Non-parametric paired data was compared by Wilcoxon signed-rank Proportions were compared by *χ* ^2^ test or Fisher's exact test (if the contingency included a number ≤ 5). Receiver Operating Characteristic (ROC) analysis was performed as a non-parametric test.

Results {#Sec6}
=======

Twenty-two HIV-1-infected adults screened for the vaccine trial with a negative TST and QFT-GIT required rescreening (due to brief suspension in recruitment) and therefore had a repeat QFT-GIT performed at a median of 62 days (IQR 49--70) after the TST. The TST was 0 mm in all participants. 90.9 % of participants were female and all were resident in Khayelitsha, a peri-urban township of Cape Town. Median age was 33 years (IQR 29--40). 16 participants (73 %) were on ART for a median of 2.0 years (IQR 1.5--3.5) and had a suppressed VL (either lower that detectable limit (LDL) or \<40 copies/mL). Seven participants (31.8 %) had been treated for active TB a median of 3.7 years previously (IQR 2.0--4.2). Median VL for those not on ART was 17,309 copies/ml (IQR 10,563--34,735). Median CD4 count for the 22 participants was 477/mm^3^ (IQR 439--621). All participants had negative sputum culture and a CXR without evidence of active TB.

Nine of 22 participants (40.9 %, 95 % CI 18.6--63.2 %) demonstrated conversion from negative (\<0.35 IU/ml) to positive QFT-GIT during the interval between tests. There was no significant difference in CD4 count, age, sex, proportion on ART, previous TB treatment or time between initial and repeat IGRA between those that converted and those that did not (Table [1](#Tab1){ref-type="table"}). However, in those who converted, the median baseline TBAg-Nil of 0.21 IU/ml (IQR 0.17--0.26) was significantly higher compared to non-converters (0.02 IU/ml, IQR 0.01--0.07, *p* = 0.002) as was the change in TBAg-Nil post TST, 0.82 IU/ml (IQR 0.39--1.28) compared to 0.03 IU./ml (IQR −0.05--0.06, *p* = 0.0001), respectively. The repeat TBAg-Nil, post TST, was significantly higher in converters (0.84 IU/ml (IQR 0.65--1.50), *p* = 0.008) but not in non-converters 0.06 IU/ml (IQR 0.00--0.10), *p* = 0.86 (Fig. [1](#Fig1){ref-type="fig"}).Table 1Table showing differences in characteristics between converters and non-convertersVariableOverall population\
*n* = 22Converters\
*n* = 9Non-converters\
*n* = 13*p*-valueAge (years) -- Med(IQR)33(29--40)32(29--40)36 (30--39)0.52Sex - Female90.9 %100 %84.6 %0.49CD4 count (/mm^3^) -- Med(IQR)477 (439 -- 621)466 (426--720)477 (458--589)0.87On ART73 %66.6 %76.9 %0.66Previous TB treatment31.8 %23.1 %44.4 %0.37Time between tests (days) -- Med(IQR)62 (49--70)50 (46--62)69 (58--71)0.11Baseline TBAg-Nil (IU/ml) -- Med (IQR)0.07 (0.01--0.21)0.21 (0.17--0.26)0.02 (0.01--0.07)0.002Change in TBAg-Nil (IU/ml) -- Med(IQR)0.09 (−0.05--0.62)0.82 (0.39--1.28)0.03 (−0.05--0.06)0.0001Characteristics of 9 converters and 13 non-converters compared. Gaussian distribution of data determined by Shapiro-Wilk test. Non-parametric data compared using Mann-Whitney *U* test and parametric data compared using *t*-test. Proportions were compared by *χ* ^2^ test or Fisher's exact test (if the contingency included a number ≤ 5)*Med* Median, *IQR* Interquartile range, *ART* Antiretroviral therapy, *IU* international units Fig. 1Change in QFT-GIT TBAg-Nil before and after TST. Graph showing TBAg-Nil level for participants at baseline and after boosting. Values for individual participants connected with line. Values \<0 IU/mL not shown on graph

In order to determine if a specific cut-off could effectively identify converters, ROC analysis was performed on the baseline TBAg-Nil values. Area under the curve (AUC) of baseline TBAg-Nil to identify converters was 0.87 (95 % CI 0.69--1.00). TBAg-Nil cut-off values of 0.15 IU/ml and 0.17 IU/ml both correctly classified 86.4 % of converters, with 0.15 IU/ml cut-off having a higher sensitivity (88.9 % vs 77.8 %) and 0.17 IU/ml having a higher specificity (92.3 % vs 84.6 %) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2ROC analysis. **a**. Figure showing ROC analysis for baseline TBAg-Nil to distinguish converters and non-converters. **b** Table showing sensitivity, specificity, proportion correctly classified, positive likelihood ratio and negative likelihood ratio for each cut-off value. LR + = positive likelihood ratio, LR- = negative likelihood ratio

Discussion {#Sec7}
==========

We have shown that in an HIV-1-infected population living in high TB burden setting, over 40 % of those with an initially negative QFT-GIT (TBAg-Nil \<0.35 IU/ml) and TST (\<5 mm) convert to QFT-GIT positive (TBAg-Nil ≥0.35 IU/ml) within 7--10 weeks of a TST. We have also demonstrated that converters have a higher baseline QFT-GIT TBAg-Nil and that a baseline cut-off value of 0.15 IU/ml correctly classifies 86.4 % of converters with 88.9 % sensitivity. This rate of conversion is considerably higher than in previous studies conducted in a variety of settings with low HIV prevalence \[[@CR8]--[@CR11]\].

Although our study was conducted in a setting of high TB incidence it is unlikely that the 40 % conversion rate represents acquired infection over a 7--10 week period. The estimated force of infection in this setting is less than 8 % per year, therefore the expected rate of new infection over a 7--10 week period would be less than 1.5 % \[[@CR13]\]. Furthermore if acquired infection was responsible for conversion, this would not be expected to relate to baseline QFN-GIT response.

Converters in our study had a significantly higher baseline TBAg-Nil than non-converters (0.21 vs 0.02). In addition to this, following TST, converters also had a significantly greater increase in TBAg-Nil with non-converters generally showing minimal change post TST (0.82 vs 0.03) demonstrating that TST did not just simply result in a uniform boosting in IFNγ production in all participants. The low baseline response and minimal boosting in non-converters in our study are similar to the responses in HIV-uninfected participants that are TST and QFT-GIT negative (\<0.35 IU/mL) at baseline. Sauzullo et al. found 69 TST negative Italian healthcare workers to have QFT-GIT TBAg-Nil \<0.03 IU/ml and \<0.08 IU/ml before and 6 weeks after TST, respectively \[[@CR8]\]. By contrast, previous studies have demonstrated that persons with positive QFT-GIT (\>0.35 IU/mL) at baseline are more likely to show an increase in TBAg-Nil following TST than those with a negative QFT-GIT \[[@CR14]\].

Taken together, our data supports the possibility that within this population of HIV-1-infected persons with negative TST and QFT-GIT there may be 2 distinct populations. A true negative group that have no evidence of immune sensitization by Mtb even following stimulation with mycobacterial peptides in the form of PPD and a false negative group that show initial evidence of weak antigen specific immune response to Mtb, as determined by IFNγ release in whole blood stimulated by ESAT-6, CFP-10, and TB7.7, that can be boosted by intra-dermal PPD injection. One explanation for this phenomenon is that pre-existing memory responses may be stimulated by PPD (which include antigens ESAT-6 and CFP-10) when TST is performed \[[@CR15]\]. This may lead to proliferation of antigen specific effector cells which may then be present in greater numbers when peripheral blood is restimulated *ex vivo* when the repeat QFT-GIT is performed resulting in greater IFNγ release, and a positive QFT-GIT. Our data also suggest that a lower cut-off may improve sensitivity of QFT-GIT for the detection of latent TB in HIV-1-infected persons. Intuitively, having a lower cut-off in HIV-1-infected persons for an immune-diagnostic test is logical as the cells which contribute to a positive result are especially susceptible to HIV-1 induced depletion \[[@CR2]\].

A limitation of the study was that we were unable to validate a lower cut-off for QFT-GIT in HIV-1-infected persons. It would also be important to ensure that any novel cut-off for HIV-1-infected persons was validated for a range of CD4 counts. Furthermore our study was only conducted using QFT-GIT, it would be of interest to determine if a similar phenomenon occurred using the TSPOT.*TB* assay. It was beyond the scope of the study to investigate whether participants that converted had any immunological differences in phenotype or function of antigen specific T cells in comparison to non-converters. In particular it would be of interest to investigate if converters had evidence of antigen specific central memory responses not present in non-converters as this would have supported the assertion that they represented distinct subgroups.

Conclusion {#Sec8}
==========

We have demonstrated that in an HIV-1 infected population with negative QFT-GIT and TST (that would conventionally be characterised as not having latent TB infection and not considered for IPT) there are 2 distinct groups. One group shows evidence of a weak Mtb specific immune response that boosts significantly following TST resulting in conversion of the test result and may represent a false negative group that may benefit from IPT. We propose that a lower cut off, between 0.15 and 0.17, may improve sensitivity of QFT-GIT and warrants further validation.

Additional file {#Sec9}
===============

Additional file 1: Table S1.Demographics and data for the 22 participants in study. (XLSX 63 kb)

ART

:   Antiretroviral therapy

CXR

:   Chest radiograph

FIND

:   Foundation of Innovative new diagnostics

GLP

:   Good laboratory practice

IGRA

:   Interferon gamma release assays

IQR

:   Interquartile range

IU

:   International units

Med

:   Median

Mtb

:   *Mycobacterium tuberculosis*

QA

:   Quality Assurance

ROC

:   Receiver operating characteristic

TB

:   Tuberculosis

TST

:   Tuberculin skin testing

Katalin A. Wilkinson and Robert J. Wilkinson are joint senior authors.

The authors would like to thank Fadheela Patel and Zeinonissa Latief for assistance with laboratory processing of samples and the clinic team at the Khayelitsha site of the MVA85A trial for assistance with recruitment and sampling of participants.

Funding {#FPar1}
=======

This work was supported by the Wellcome Trust (090170) and the European & Developing Countries Clinical Trials Partnership (IP.07.32080.002). Funders did not play a role in design of the study, analysis and interpretation of data or in writing the manuscript.

Availability of data and materials {#FPar2}
==================================

The dataset supporting the conclusions of this article is included within the Additional file [1](#MOESM1){ref-type="media"}: Table S1.

Authors' contributions {#FPar3}
======================

H.E., K.A.W., and R.J.W. designed the study; H.E., F.T., T.O. and R.G recruited and screened participants for study entry; H.E. and K.A.W. analyzed data, H.E., K.A.W. and R.J.W wrote the manuscript and subsequently all authors provided advice and approved the final manuscript.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Consent for publication {#FPar5}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar6}
==========================================

The study adhered to International Conference on Harmonisation Good Clinical Practice guidelines, and was approved by the University of Cape Town's Faculty of Health Sciences Human Research Ethics Committee. All participants provided written informed consent.
